Targeting Hexokinase II in Chemotherapy

描述（由申请人提供）：己糖激酶II（HXK II）控制糖酵解的第一步，将葡萄糖磷酸化为葡萄糖-6-磷酸（G-6-P）。癌细胞过度表达HXK II，其中大多数通过与VDAC-1（电压依赖性阴离子载体）（一种丰富的线粒体外膜蛋白（OMM））的相互作用结合到线粒体。HXK II与癌细胞中线粒体的结合增强，加速了糖酵解的速率，从而为氨基、核酸和脂肪酸合成提供了充足的前体供应。线粒体已成为细胞凋亡和坏死中细胞死亡途径的重要组成部分，线粒体膜间隙蛋白的释放在细胞活力的执行和最终死亡中至关重要。促凋亡蛋白如Bax、Bid和Bim可能通过与VDAC-1相互作用诱导线粒体功能障碍，从而引起膜间空间蛋白的释放。对于这一提议，我们的工作假设是，HXK II与线粒体的结合增加对于为癌细胞提供维持其加速增殖速率所需的代谢谱至关重要。此外，HXK II与线粒体的结合通过防止促凋亡蛋白如Bax、Bim和Bid诱导线粒体功能障碍来帮助癌细胞的存活和对化疗剂的抗性。HXK II在线粒体中的定位部分受PBR和糖原合成酶激酶3 P（GSKP）的活性控制。这些假设得到初步结果的支持，表明重组HXK II的能力，以防止Bax的结合和释放细胞色素c从分离的线粒体和增强的敏感性转化细胞表现出的范围内的化疗药物后，分离的线粒体结合HXK II。抑制PBR介导的胆固醇摄取和磷酸化的VDAC-1的GSK 3？导致HXK II从线粒体脱离，随后发展为对化疗诱导的细胞死亡的敏感性增强。该项目的总体目标是提供对线粒体结合的HXK II增加癌细胞增殖和存活的机制的更深入理解，并阐明HXK II与线粒体的结合是如何调节和维持的，目的是利用HXK II与线粒体的结合作为抗癌靶点。

DESCRIPTION (provided by applicant): Hexokinase II (HXK II) controls the first step in glycolysis, phosphorylating glucose to glucose-6-phosphate (G-6-P). Cancer cells over-express HXK II with the majority being bound to the mitochondria through an interaction with VDAC-1 (voltage dependent anion carrier), an abundant outer mitochondrial membrane protein (OMM). The enhanced binding of HXK II to mitochondria in cancer cells accelerates the rate of glycolysis, thus providing an ample supply of precursors for amino, nucleic and fatty acid synthesis. Mitochondria have emerged as an important component of the cell death pathway in both apoptosis and necrosis, with the release of mitochondrial intermembrane space proteins being critical in the execution and ultimate demise of cellular viability. Proapoptotic proteins such as Bax, Bid and Bim induce mitochondrial dysfunction, possibly by interacting with VDAC-1, thereby provoking the release of intermembrane space proteins. For this proposal our working hypothesis is that the increased binding of HXK II to mitochondria is critical for providing cancer cells with the necessary metabolic profile for maintaining their accelerated rate of proliferation. Additionally, HXK II binding to mitochondria aids in the survival and resistance of cancer cells to chemotherapeutic agents by preventing proapoptotic proteins such as Bax, Bim and Bid from inducing mitochondrial dysfunction. The localization of HXK II to mitochondria is controlled in part by the activity of the PBR and glycogen synthase kinase 3P (GSKP). These hypotheses are supported by the preliminary results demonstrating the ability of recombinant HXK II to prevent Bax from binding to and releasing cytochrome c from isolated mitochondria and the enhanced sensitivity exhibited by transformed cells to a range of chemotherapeutic agents upon the detachment of mitochondrial bound HXK II. Inhibition of PBR mediated cholesterol uptake and phosphorylation of VDAC-1 by GSK3? resulted in a detachment of HXK II from mitochondria with the subsequent development of enhanced sensitivity to chemotherapy induced cell death. The general goals of this project are to provide a deeper understanding of the mechanism(s) by which mitochondrial bound HXK II increases the proliferation and survival of cancer cells and to elucidate how HXK II binding to mitochondria is regulated and maintained, with the goal of exploiting the binding of HXK II to mitochondria as an anti-cancer target.